Peptron Receives Patent Approval for Tirzepatide Long-Acting Formulation
Applicable to Long-Acting GLP-1 Formulations Including Semaglutide and Tirzepatide
Strengthening Pipeline IP for Obesity and Metabolic Disorders Based on SmartDepot™
Peptron, a company specializing in developing sustained-release peptide-based pharmaceuticals, announced on October 1 that it has received approval for a domestic patent registration for its long-acting formulations that can be applied to GLP-1 class drugs such as semaglutide and tirzepatide.
This patent relates to sustained-release formulation technology that enables the long-term release of GLP-1 class drugs. It represents a key intellectual property right for applying Peptron's long-acting drug delivery platform, SmartDepot™, to the field of obesity and metabolic disorders.
Peptron is currently developing a semaglutide-based long-acting treatment (PT403), which is administered once a month, as well as a tirzepatide-based long-acting formulation (PT404). The company is pursuing both in-house development and global business development activities.
According to Peptron, this registration decision strengthens its domestic rights foundation for long-acting formulations of major GLP-1 class drugs and secures intellectual property that can be leveraged in future global partnering and commercialization initiatives.
Peptron is also seeking to secure patent rights in major overseas countries by filing corresponding applications internationally. Depending on the examination results of each country's patent office, registration eligibility will be determined for each region.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Peptron representative stated, "The approval of this patent registration is significant as it further strengthens the intellectual property foundation for GLP-1 long-acting formulations utilizing SmartDepot™," adding, "We will continue to expand our business development opportunities with global pharmaceutical companies alongside the development of PT403 and PT404 so that these efforts lead to the successful commercialization of long-acting formulations."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.